INCY
★★★★★ Strong BuymistralIncyte Corporation
Healthcare · sector percentile 100
세션 움직임
$123.47
거래량 0.65× 평균
90/100 quant · tgt $125.17
RS60 +23.2% vs SPY · ADV$ 224.7M
푸시 2026-08-19T12:28 · 프리마켓 · 푸시 스냅샷
직전 스캔 대비
2026-08-18 → 2026-08-19
참고용이며 매수/매도 신호가 아닙니다. 스캔 이력과 캐시된 뉴스·공시로 구성됩니다.
스냅샷 시세
세션 2026-08-18 · 스캔 2026-08-19 · 푸시 2026-08-19T12:28 · 프리마켓
시세 상세 보기시세 상세 숨기기
- 종가/스캔가
- $123.47
- 전일 종가
- $123.50
- 푸시 최신가
- $123.47 · 프리마켓
- 세션 시가
- $124.29
- 직전 세션 범위
- $123.23 – $124.71
- 52주 범위
- $81.09 – $132.60
- 세션 거래량
- 1,191,123
- 평균 거래량 (20일)
- 1,836,831
- 시가총액
- $25.03B
- PER (TTM)
- 15.71
- Forward PER
- 13.90
- 배당 수익률
- 0.00%
- 1년 목표가 추정
- $125.17
- 다음 실적
- 2026-10-27
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. 프리/애프터 시세는 유동성이 얇아 정규장과 다를 수 있습니다.
$1,000 넣었다면 지금
1년 전
$1,445
+44%
5년 전
$1,648
+65%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
시장 브리핑
선별된 요약입니다 — 매매 신호가 아닙니다. 헤드라인·링크는 제공된 그대로 표시됩니다.
- Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Benzinga · 2026-08-17
- Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.
ChartMill · 2026-08-17
- IHF: Healthcare Dashboard For August
Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.
SeekingAlpha · 2026-08-17
- Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]
Yahoo · 2026-08-14
레딧 언급
공식 Reddit API로 가져온 공개 글 제목입니다 — 비공식·지연될 수 있으며 매매 신호가 아닙니다. Reddit과 제휴하지 않습니다. 링크는 Reddit으로 이동합니다.
이 종목과 맞는 최근 레딧 제목이 없습니다.
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — Incyte's 93/100 quant score reflects strong revenue/EPS growth (37.7% YoY), high ROE (30.7%), and consistent FCF margins (20.3%), positioning it well in specialty oncology.
- Risks — Form 4 insider selling (-15 disclosure score) and high 3-month volatility (38.3%) may signal near-term caution despite quant strength.
- Target Upside — Mean analyst target of $125.17 implies 1.4% upside from $123.47, with momentum (29.7% 3M) and earnings surprise (44.6%) supporting valuation.
Score History
17 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-08-19$123.47-0.0390.1Strong Buy
- 2026-08-18$123.50+3.3490.1Strong Buy
- 2026-08-17$120.16-0.3691.0Strong Buy
- 2026-08-14$120.52+0.4090.9Strong Buy
- 2026-08-13$120.12-0.9591.0Strong Buy
- 2026-08-12$121.07-0.4890.7Strong Buy
- 2026-08-11$121.55+0.9990.5Strong Buy
- 2026-08-10$120.56+0.0090.8Strong Buy
- 2026-08-09$120.56+0.0093.8Strong Buy
- 2026-08-08$120.56+2.1893.8Strong Buy
- 2026-08-07$118.38-1.4290.9Strong Buy
- 2026-08-06$119.80-0.8091.0Strong Buy
- 2026-08-05$120.60+2.1790.8Strong Buy
- 2026-08-03$118.43-1.0990.9Strong Buy
- 2026-08-01$119.52-0.1390.6Strong Buy
- 2026-07-31$119.65-3.3490.5Strong Buy
- 2026-07-30$122.99—89.6Buy
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 71.4%
- vs 20d (z)
- 1.36
- Short vol
- 256,443
- Status
- ok
Squeeze pressure score
full44/100
- Short leg
- 40
- Call leg
- 63
- Activity
- 1.0
- Call vol share
- 76.8%
- PCR (vol)
- 0.30
- Call OI share
- 51.6%
- ATM IV
- 47.0%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
공시 점수 (Disclosure)
캐시된 SEC 공시 기반 News / Insider / Earnings 규칙 다리 — 참고용이며, beat/miss나 매수 신호가 아닙니다.
공시 점수
-15
- News
- 0
- Insider
- -15
- Earnings
- 0
아래 신호는 캐시된 공시의 규칙 히트입니다 — Risk / Constructive / Attention. Attention은 상승 신호가 아닙니다. 링크된 칩은 SEC 원문으로 이동합니다.
Risk (−)
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
실적 서프라이즈 (퀀트 맥락)
최근 퀀트 스캔에 캐시된 Yahoo/공개 펀더멘털 수치입니다 — 공시 이벤트 점수에 합산되지 않으며 매수 신호가 아닙니다. 최신 발표보다 늦을 수 있습니다.
최근 보고 서프라이즈 +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-27yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-14
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗10-Q2026-07-28
10-Q
- SEC ↗8-K2026-07-28
8-K
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-20
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.